Hints and tips:
...Justice, intend to follow through on their mission to draw a tougher line on antitrust.Still outstanding are large contested deals, including Amgen’s planned $28bn takeover of Horizon Therapeutics and Pfizer...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...The five-time premier is counting on Israel emerging from the pandemic on the back of the vaccine-procurement initiative just in time to seal his re-election and distract attention from his ongoing trial...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...Russia’s Sputnik V jab carries deliberate cold war echoes....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
...ICU is in the process of integrating its $900m acquisition of Hospira Infusion Systems last year from Pfizer, a business that Smiths had also been interested in purchasing....
...A decade ago, Jeffrey Kindler, then chief executive of US drugs giant Pfizer, was plotting an audacious $68bn acquisition of rival Wyeth....
...It has shut down one of its main engineering sites, making about 40 staff redundant, and put the V-Charge on ice....
...It was not only the corporate tax rate itself — the highest in the developed world — to which Pfizer objected but also its scope....
...In March 2015, he fought off stiff competition from Johnson & Johnson and Pfizer to seal the $21bn purchase of Pharmacyclics, the maker of a blockbuster drug for blood cancers....
...It would have annual revenues in excess of $65bn, drawn from drugs including Pfizer’s pneumonia vaccines and Botox, the wrinkle smoother made by Allergan....
...AstraZeneca will need to make a lot more announcements like this morning’s to justify the optimism that saw it reject a bid from Pfizer last year. The US drugs group offered £55 per share....
...The owner of British Airways and Iberia can launch a new offer bearing the same seal of approval three months after the old one lapses....
...Valeant only managed to seal the Salix deal after it raised its offer to $173 a share in response a counterbid from Endo....
...Team Pfizer clearly did not do enough studying, misreading the political sentiment and miscalculating the price they needed to pay to seal the deal....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...The speed with which he has upped his offer after wooing City investors this week suggests he wants to seal a deal before protectionist forces have fully mobilised....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Greece debt restructuring - Inflation fears resurface on rising clothes prices - George Osborne tax will push up household bills - UK new car sales fall for tenth month in April - Pfizer...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Toby Chandler, co-investment chief of Seal Capital, says there is a greater need for global macro to act as a hedge against potential systematic risk events in the future, notably in Europe....
...Deltacortril, which Alliance acquired from Pfizer in 2006, was the main driver of the sales growth....
International Edition